Skip to main content
Clinical Trials/NCT05079386
NCT05079386
Completed
N/A

Early Clinical Feasibility Study of a New Voice Prosthesis

Atos Medical AB1 site in 1 country17 target enrollmentJanuary 7, 2022
ConditionsLaryngectomy

Overview

Phase
N/A
Intervention
Not specified
Conditions
Laryngectomy
Sponsor
Atos Medical AB
Enrollment
17
Locations
1
Primary Endpoint
Patient acceptability
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The objective of this clinical investigation is to evaluate the short-term clinical feasibility of a new voice prosthesis and explore its acceptability, limitations and advantages. As a result of the evaluations, design changes may be implemented and evaluated until the optimal design has been determined, or until it is decided not to pursue further development of the device. Main outcome will be the patient's acceptance of the voice prosthesis, secondary outcomes are stickiness of the valve mechanism and speech.

Registry
clinicaltrials.gov
Start Date
January 7, 2022
End Date
January 27, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Laryngectomized patients using either the Provox Vega 22.5 or the Provox ActiValve Light voice prosthesis, with a length of 4, 6, 8, or 10 mm
  • 18 years and older

Exclusion Criteria

  • Current tracheoesophageal puncture problems such as enlarged puncture or infection
  • Active recurrent or metastatic disease (medical deterioration)
  • The use of ActiValve Strong/XtraStrong or XtraSeal
  • Unable to understand the Patient Information and/or unable to give Informed Consent
  • The previous 2 VPs had a device lifetime \> 12 months
  • History of oral resections negatively affecting speech

Outcomes

Primary Outcomes

Patient acceptability

Time Frame: 2 week

Patient recorded acceptability of the voice prosthesis based on study specific questionnaires covering: 1) Experienced stickiness, 2) Effort to speak and 3) maintenance of voice prosthesis. Assessed by Yes/No and multiple choice questions.

Secondary Outcomes

  • Voice Assessment - Maximum phonation(Baseline and 2 weeks)
  • Voice Assessment - Highest volume(Baseline and 2 weeks)
  • Voice Assessment - Lowest Volume(Baseline and 2 weeks)
  • Quality of Life by EQ-5D-5L(Baseline and 2 weeks)
  • Voice Assessment - Glide tones(Baseline and 2 weeks)
  • Device life(Baseline, and week 52)
  • Voice Assessment - Softness(Baseline and 2 weeks)
  • Voice Assessment - Loudness(Baseline and 2 weeks)
  • Voice Handicap Index - 10(Baseline and 2 weeks)

Study Sites (1)

Loading locations...

Similar Trials